Company Overview

Ansella Therapeutics is specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes. The company’s initial focus is on women’s health, specifically in the development of novel vaginal formulations.

Biomimetics is an interdisciplinary field in which principles from engineering, chemistry and biology are applied to the synthesis of materials, or synthetic systems that have functions that mimic biological processes. Biomaterials are any natural or synthetic material that interacts with any part of a biological system. Biomimetic designs can be used in regenerative medicine, tissue engineering and drug delivery.

Ansella Therapeutics utilizes its expertise in materials science and biomedical engineering to create unique, enhanced therapeutic approaches inspired by inherent anatomy, physiology, biochemistry, and endocrinology.

The company has launched its first product, Cerynë Intimate Care, for women with everyday vaginal dryness and designed for vulvovaginal application. Cerynë Intimate Care is the world’s first biomimetic formulation which works with your body to restore comfort and balance.

Cerynë Intimate care has been launched both directly to consumers and through physician channels as an intimate care product for vaginal dryness.

Ansella Therapeutics is developing a range of treatment that focus on Women’s Health including Menopause, Vaginal mucositis, Endometriosis, Uterine Fibroids and vaginal Infection.

Company overview

Avive Solutions is a MedTech company that has developed a next-generation automated external defibrillator (AED) and software solutions that revolutionizes the current sudden cardiac arrest (SCA) response. 

The device aims to significantly increase survival rates from SCA. 

The $3.5 billion global external defibrillators market is projected to have 9.7% compounded annual growth rate (CAGR) from 2024 to 2030. The AED market growth is  driven by legislation, property development and hospital groups, which has caused a shift in customer awareness and push for inbound sales models that the large players generally ignore in favor of entrenched distributor relationships.

The current SCA response system has a 10% survival rate, but when AEDs are used, the survival rate increases to over 40%.  The low AED usage is due to limited availability, improper maintenance, and a lack of connectivity in current AED machines. 

Avive’s automated external defibrillator (AED) device is a next-generation IoT (internet-of-things) device with complementary software solutions that has the ability to transform the existing flawed system for responding to Sudden Cardiac Arrest (SCA). Their system automates AED maintenance, tracks the AED, provides remote software updates, and automatically shares rescue data with emergency services, effectively eliminating the issues plaguing current aed machines. Their goal is to get an AED to a patient in under 4 minutes compared to the normal standard response time for emergency services which is 12 minutes. 

Cofounder: Sameer Jafri

Smeer is one of the Founders of Avive, and serves as the CEO. His most recent role prior to founding Avive was as the Founder & President of Saving Hearts Foundation, a non-profit based in Los Angeles that is focused on Sudden Cardiac Death (SCD) prevention. The foundation has hundreds of volunteers across the Greater Los Angeles Area, and physician support from industry leading cardiologists and electrophysiologists from UCLA, Kaiser Permanente, HCA, and others. Sameer received his Bachelor’s degree in Political Science from UCLA.

Cofounder: Rory Beyer

Rory is one of the Founders of Avive and serves as the President / COO. His most recent role prior to founding Avive was as a product design engineer at Apple, where he contributed to the development and design of future generation accessory products. Rory received his Bachelor’s degree in Electrical Engineering and Computer Science, as well as Mechanical Engineering from MIT. During his time at MIT, Rory held numerous leadership roles in MIT research projects, including among others the electronics development of a car powered completely by Aluminum fuel.

Cofounder: Moseley Andrews

Moseley is one of the Founders of Avive, and serves as the CTO. His past experience and passion has revolved around developing innovative healthcare technology. His most recent role prior to founding Avive was working as a researcher at the MIT Media Lab where he helped develop novel sensing and imaging techniques. Moseley received his Bachelor’s degree in Mechanical Engineering from MIT, and while obtaining his degree he led multiple engineering projects that included rehabilitation products for spinal cord, stroke, and brain trauma as well as keyhole neurosurgical instrument design.

Company Overview

Caresyntax has developed an enterprise-grade surgical intelligence system that is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. This allows the platform to generate insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery.
The Company has a footprint in 3,000 operating rooms, has been used in over 3 million surgeries, and has over 30,000 surgical users.

COFOUNDER AND CFO: Björn VON SIEMENS

Mr. Björn Von Siemens is a Co-Founder and serves as Co-Chief Financial Officer, Chief Business Officer & Board Member, Owner and Managing Director at Caresyntax. Mr. Siemens is a Co-Founder and serves as Managing Director at Surgical.ai. He serves as Chairman at Lillian Care. He serves as Board Member at Daslab. Hailing from a family of tech industrialists and medical thought leaders, Björn possesses a native drive and understanding for applying technologies to solve challenges in healthcare.

CoFounder and CEO: Dennis Kogan

Mr. Dennis Kogan is a Co-Founder and serves as Chief Executive Officer, President, and chairman at Caresyntax. He is a Co-Founder and serves as Managing Director & Managing Partner at surgical.ai. He graduated from Carnegie Mellon and Harvard Business School with degrees in information technology, finance, and business administration. He has more than 10 years of experience in financial and strategy consulting in the medical device and IT sectors. He possesses a keen awareness of the impact that new technologies can bring to surgical innovation. Dennis provides strong leadership and a clear strategic direction for Caresyntax.

Company overview

Edeavors ENV-101 is a second-generation Hedgehog inhibitor with a highly favorable efficacy and side-effect profile compared to the molecules currently in the market. ENV-101 inhibits target pathway by ~90% at all tested doses.

Currently Hedgehog inhibitors are indicated for basal cell carcinoma. Significant data indicates the pathway involvement in fibrosis of the lungs. ENV-101 represents a significant improvement on existing therapies for IPF and is expected to be the Best-in-Class Hedgehog Inhibitor.

Attractive white space in the market
IPF market estimated to be $8.8B by 2027. SOC (standard of care), i.e., Boehringer Ingelheim’s Nintedanib (Ofev) has current sales >$3B with <20% market penetration based on prescription data. Current SOC has poor tolerability and efficacy.

Roche acquired InterMune in 2014 for $8.3 billion for Pirfenidone (Esbriet), indicated for IPF. Esbriet lost exclusivity in 2022 and Ofev is expected to lose exclusivity in 2025; which gives the next blockbuster significant white space for pricing and reimbursement. Both Ofev and Esbriet have severe and limiting GI issues for patients which ENV-101 seems to address.

Cofounder: Dr. John Hood

Dr. Hood is a veteran of the California life science community who has founded and led several successful biotechnology companies in his 20-year career. He is currently Founder, CEO and Executive Chairman of Endeavor Biomedicines. Prior to that, John was the Founder and CEO of Impact Biomedicines (now owned by Bristol-Myers Squibb), the developer of fedratinib, which has subsequently been approved worldwide for the treatment of myelofibrosis. He began his career as Director of Research at TargeGen in 2001, where he co-discovered fedratinib. John is an inventor on 100+ patents and the author of 50+ scientific articles. He received his Ph.D. in Medical Physiology and a B.S. in Biochemistry from Texas A&M University.

Cofounder: Dr. Miguel de los rios

Miguel de los Rios is an entrepreneur focused on developing novel therapeutics to satisfy unmet needs in human medicine. Prior to Endeavor, he was Founder and CEO at Rift Biotherapeutics, a therapeutic antibody company focused on cancers. Prior to that Miguel served as Vice President of Research and Development at Sevion Therapeutics (formerly Fabrus, Inc.), a clinical stage therapeutics company focused in oncology and autoimmune disorders. Miguel founded Chimeros, Inc., a venture-backed biologics therapeutic company in 2003 while working to complete his PhD. He is lead author or inventor on 50+ publications, patents and patent applications. He received his Ph.D. in Biophysical Chemistry and a B.S. in Cell Biology, both at UC Santa Barbara.